Form 4: Neumora Therapeutics Director Receives Stock Options

Director Alaa Halawa was granted 80,000 stock options in Neumora Therapeutics, Inc. as part of a standard equity compensation arrangement.

Summary

• Director Alaa Halawa acquired 80,000 stock options in Neumora Therapeutics, Inc. (NMRA).
• The options have an exercise price of $1.86 per share.
• The grant date for the transaction was May 27, 2026.
• The options are set to expire on May 26, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard corporate governance and compensation practices.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $1.86 exercise price.

Future Outlook

The options vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the next Annual Meeting following May 27, 2026.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board talent, though they represent a minor dilutive factor.

Comparison to Industry Standards

• The vesting schedule is consistent with standard one-year cliff vesting for board members in the life sciences industry.
• The grant size is typical for non-executive director compensation packages in mid-cap biotech firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon potential future exercise of options.

Next Steps

• Vesting of options on May 27, 2027, or the date of the next Annual Meeting.

Key Dates

Keywords

Neumora Therapeutics, NMRA, Form 4, Insider Trading, Stock Options, Director Compensation